1. Control and Prevention of MDR-TB in the Greater Mekong Sub-region CAP-TB PROJECT

2. Strengthening the health system through basic building blocks for TB control

3. CAP-TB Strategic Model

4. Integration with the health system for TB control and prevention

5. Implementing innovative strategies with long-term sustainability

7. CAP-TB Strategy for FY14 Evaluate implementation to date (FY12-FY13) Identify successful strategies to continue and potentially scale up – Increased case detection and treatment success as “downstream” indicators of impact Review current literature for recent evidence on potential innovations, etc., that can be piloted through the project

8. Lancet Infectious Disease Vol 13, No 7, July 2013 WHO analysis of 30 countries to determine progress toward universal access to MDR- TB care by 2015

9. cv

11. Lancet Infectious Disease Vol 13, No 7, July 2013 Major Findings 6 of 30 countries will reach goal for universal MDR-TB access by 2015. 19 of 30 countries (including Myanmar, China, Thailand) need significant help to reach 2015 goal. Challenges: Lab capacity; “treatment gap” between detection and enrollment; poor treatment outcomes in some settings.

12. Lancet Infectious Disease Vol 13, No 7, July 2013 Recent literature emphasizes the importance of MDR-TB decentralization

13. Thailand Support BTB to develop infrastructure for national MDR-TB decentralization network – Rayong as pilot model for provincial-level decentralization Continue Rayong Hospital activities: call center, MDR-TB case conferences, multi-disciplinary teams for MDR-TB care Active case finding (DM, PLHIV clinics) and community support: assess donor funding and existing support

14. Building a provincial model for TB/MDR-TB decentralization in Rayong: Strengthening provincial, district, sub-district, and community levels of TB network

15. Thailand Support BTB to develop infrastructure for national MDR-TB decentralization network – Rayong as pilot model for provincial-level decentralization Continue Rayong Hospital activities: call center, MDR-TB case conferences, multi-disciplinary teams for MDR-TB care Active case finding (DM, PLHIV clinics) and community support: assess GFATM funding and existing capacity

16. Myanmar: Integration with the TB network to strengthen TB control

17. Myanmar Continue with patient treatment support Identify risk groups for piloting innovative methods to improve case detection/treatment success – Childhood TB – Other risk groups: DM, PLHIV, etc. Organizational Capacity Development

18. Case notifications MDR-TB (2008-2013) YearCases (Solid/Liquid Culture/LPA) Cases put on SLD 2010312192 2011690162 2012778442 2013 (Q1)42665 2013 (Q2)376218

20. Engage community volunteers (in addition to health care workers) Provide DOT throughout treatment Limit cohort size: decentralization Provide patient education Provide package of adherence interventions Provide standardized regimen (not individualized)

21. Myanmar: Identifying TB/MDR-TB risk groups to increase detection, enrollment, and treatment success

22. Myanmar Continue with patient treatment support Identify risk groups to improve case detection and treatment success – PLHIV, geographic areas (border and remote) with high treatment interruption/default rates, etc. Organizational Capacity Development Research: health financing, gender, 9 month “short regimen”

23. China: Implementing innovative strategies with long-term sustainability

24. Reported incidence (1/100,000) National average Yunnan Reported pulmonary TB incidence of Yunnan compared with national average (1997-2012) The reported TB incidence has remained relatively stable since 2006 in Yunnan, compared to a decline in the national incidence.

25. China Refine strategy for case-finding interventions to scale up: – Analyze data from FY13 to identify most effective strategies – DM/TB, private clinics/pharmacies, QQ groups, PLHIV, community engagement (Women’s Federation) Engagement of private sector: #3 Hospital of Kunming Potentially for FY15, consider piloting CAP-TB model in Zhao Tong prefecture: “chronic TB outbreak” – Would enable Yunnan to have both an urban and rural model for TB/MDR-TB control

26. Yunnan Province: 16 prefectures (2012) Cases 4663 3000- ﹤ 4000 2000- ﹤ 3000 1000- ﹤ 2000 500- ﹤ 1000 196- ﹤ 500 Zhao Tong Qu Jing Wen SHan Hong He Da Li Kun Ming Di Qing Chu Xiong Pu Er Xi Shuang Ban Na Lin Cang Li Jing De Hong Bao SHan Nu Jiang Yu Xi

27. FY14 – FY16 Strategic Planning Continue integrated “Health System Strengthening” – model for service delivery Implement innovation: – Focus on risk groups for TB/MDR-TB PLHIV, DM/TB, Migrant/mobile population Workplace interventions for those with risk for occupational lung disease (miners and those with pulmonary silicosis) Childhood TB, smokers, closed/congregate settings – QQ (China Facebook/Twitter): social media, “mHealth”

28. FY14 – FY16 Strategic Planning Continue integrated “Health System Strengthening” – model for service delivery Implement innovation: – Focus on risk groups for TB/MDR-TB PLHIV, DM/TB, Migrant/mobile population Workplace interventions for those with risk for occupational lung disease (miners and those with pulmonary silicosis) Childhood TB, smokers, closed/congregate settings – QQ (China Facebook/Twitter): social media, “mHealth”

29. FY14 – FY16 Strategic Planning Research – Health financing/cost-effectiveness – TB gender disparity – 9 month “short regimen” for MDR-TB Identify strategies for sustainability – Counterpart funding from national and provincial government (China, Thailand) – Capacity building of Myanmar IAs to prepare for future funding from international donors (USAID, GFATM, etc)

31. 9 month “short regimen” for MDR-TB Am J Respir Crit Care Med Vol 182. pp 684–692, 2010

32. 9 month “short regimen” for MDR-TB Am J Respir Crit Care Med Vol 182. pp 684–692, 2010

33. 9 month gatifloxacin-based regimen: 87.9% treatment success Am J Respir Crit Care Med Vol 182. pp 684–692, 2010

34. WHO Criteria for 9-Month Regimen Approval by a national ethics review committee Treatment delivered under operational research conditions following international standards to assess the safety and effectiveness of regimen Programmatic management of drug-resistant TB and the research project are monitored by an independent monitoring board set up by, and reporting to, WHO http://www.who.int/tb/challenges/mdr/short_regimen_use/en/index.html

35. 9 month MDR-TB Regimen Funding – China: national/provincial governments – CAP-TB/IUATLD: primarily technical support Drug supply – Domestic versus other Patient follow-up – Resources (human and financial) Site-training – clinical monitoring, DOT